These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30337472)

  • 21. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
    Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
    Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of safety-related regulatory action on clinical practice: a systematic review.
    Piening S; Haaijer-Ruskamp FM; de Vries JT; van der Elst ME; de Graeff PA; Straus SM; Mol PG
    Drug Saf; 2012 May; 35(5):373-85. PubMed ID: 22480319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of alternative cost recovery schemes on access and equity in Niger.
    Diop F; Yazbeck A; Bitrán R
    Health Policy Plan; 1995 Sep; 10(3):223-40. PubMed ID: 10151841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment.
    Ho C; Lim HJ; Regier DA
    Curr Oncol; 2022 Jan; 29(2):402-410. PubMed ID: 35200536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of drug coverage before and after the implementation of Canada's Common Drug Review.
    Gamble JM; Weir DL; Johnson JA; Eurich DT
    CMAJ; 2011 Nov; 183(17):E1259-66. PubMed ID: 22025648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of the Food and Drug Administration's and Health Canada's regulatory decisions about failed confirmatory trials for oncology drugs: an observational study.
    Lexchin J
    J Pharm Policy Pract; 2021 Oct; 14(1):93. PubMed ID: 34711285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale.
    Mintzes B; Morgan S; Wright JM
    PLoS One; 2009 May; 4(5):e5699. PubMed ID: 19479084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing of new black box warnings and withdrawals for prescription medications.
    Lasser KE; Allen PD; Woolhandler SJ; Himmelstein DU; Wolfe SM; Bor DH
    JAMA; 2002 May; 287(17):2215-20. PubMed ID: 11980521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand.
    Rawson NSB
    Regul Toxicol Pharmacol; 2019 Feb; 101():24-28. PubMed ID: 30391284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada.
    Sud A; McGee M; Mintzes B; Herder M
    Int J Drug Policy; 2022 Jul; 105():103749. PubMed ID: 35643048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Companies' statements about drugs withdrawn from the Canadian market: A descriptive analysis.
    Lexchin J
    Int J Risk Saf Med; 2021; 32(4):331-341. PubMed ID: 34057099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies.
    Hagan JB; Ender E; Divekar RD; Pongdee T; Rank MA
    Mayo Clin Proc Innov Qual Outcomes; 2022 Feb; 6(1):69-76. PubMed ID: 35024565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endovascular laser therapy for varicose veins: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(6):1-92. PubMed ID: 23074409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 36. The fall and rise of cost sharing in Kenya: the impact of phased implementation.
    Collins D; Quick JD; Musau SN; Kraushaar K; Hussein IM
    Health Policy Plan; 1996 Mar; 11(1):52-63. PubMed ID: 10155878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health Canada's Proposal to Accelerate New Drug Reviews.
    Lexchin J
    Healthc Policy; 2020 May; 15(4):26-34. PubMed ID: 32538346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.